The Effect of Lansoprazole in Combination With Ecabet Sodium for Gastroesophageal Reflux Disease

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

We will estimate the responses of lansoprazole and ecabet sodium combination therapy and compare with lansoprazole and placebo therapy in patients who need additional therapy after standard proton pump inhibitor treatment for 4week or more in recurrent gastroesophageal reflux disease.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Dexlansoprazole; Ecabet; Lansoprazole

Criteria

Inclusion Criteria:

• age 19-75 years

• patients with typical gastroesophageal symptom or erosive reflux esophagitis on gastroduodenoscopy

• patients with recurrent gastroesophageal symptom after standard proton pump inhibitor treatment for 4 weeks or more

Exclusion Criteria:

• patients with gastric ulcer or duodenal ulcer

• patients with gastric cancer or esophageal cancer

• pregnant or postpartum women